Results 81 to 90 of about 61,036 (213)

An overview of the pharmacology of imipenem/cilastatin [PDF]

, 1986
Imipenem is the first clinically available carbapenem antibiotic. Since it is hydrolysed by dehydropeptidase-I, a zinc metallo-enzyme resident in the brush border of the renal tubule, it is co-administered with cilastatin, a reversible inhibitor of this ...
George L. Drusano
core  

Clinical characteristics, specific resistance patterns, and molecular mechanisms of carbapenem-resistant Morganella morganii isolates

Frontiers in Cellular and Infection Microbiology
ObjectivesThe emergence and spread of carbapenem-resistant Morganella morganii (M. morganii) pose a serious global challenge. This study aimed to investigate the clinical characteristics, resistance patterns, and molecular mechanisms of carbapenem ...
Xiangkuo Zheng, Xiangkuo Zheng, Weiliang Zeng, Yan Liu, Luozhu Feng, Jiayin Zheng, Tieli Zhou, Changrui Qian, Cui Zhou   +8 more
doaj   +1 more source

Pharmacokinetics of imipenem in healthy volunteers [PDF]

, 1983
The pharmacokinetics of imipenem were evaluated in four studies involving 49 healthy men, several of whom participated in more than one study. Within a dose-range of 150 to 1000 mg, imipenem was found to give high plasma concentrations, proportional to ...
Barbro Bjornegard, Keith H. Jones, Francoise Ferberf, S. Ragnar Norrby   +3 more
core  

Sensitivity of EMRSA-15 to imipenem by E strip testing. [PDF]

, 2013
a) MIC of 4 µg/ml imipenem was seen on Mueller Hinton agar. b) MIC of 0.032 µg/ml imipenem was seen on Mueller Hinton agar containing 5% (w/v) manuka honey.
Rowena Jenkins (305364), Rose Cooper (305366)   +1 more
core   +1 more source

Population Pharmacokinetic and Exposure‐Response Analysis of Vancomycin Nephrotoxicity in Cystic Fibrosis Patients

Pediatric Pulmonology, Volume 61, Issue 8, August 2026.
ABSTRACT Introduction Acute pulmonary exacerbations (APE) in persons with cystic fibrosis (PwCF) are associated with a reduction in long‐term pulmonary function. Vancomycin is recommended as first‐line treatment of methicillin‐resistant Staphylococcus aureus ‐APE in PwCF.
Jessica Barry, J. G. C. van Hasselt, Michael Evans, Elizabeth B. Hirsch, Jordan Dunitz, Sarah Shockley, Joanne Billings, Sílvia M. Illamola   +7 more
wiley   +1 more source

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients [PDF]

, 1994
Nosocomial pneumonia and sepsis, as well as severe diffuse peritonitis, must be treated early in order to prevent complications such as septic shock and organ dysfunctions.
Schaad, U., Cometta, A., Huber, Olivier, Bille, J., Eggimann, Philippe, Zimmerli, W., Scheidegger, C., Ricou, B., Chiolero, R., Frei, R., Pittet, Didier, Suter, P., Auckenthaler, R., Baumgartner, J. D., Lew, Daniel Pablo, Chopart, P., Glauser, P., Herter, C.   +17 more
core   +1 more source

Treatment and Follow up of Pseudomonas Endophtalmitis due to Contact Lens Use

Medicine Science, 2013
The use of contact lenses is the most common cause of bacterial keratitis. Pseudomonas aurogenoza is the most common factor. We aimed to present diagnosis, treatment and follow up a 21 yeas old female patient with endophtalmitis secondary to multi-drug ...
Tongabay Cumurcu, Abuzer Gunduz, Mufide Cavdar   +2 more
doaj   +1 more source

Population pharmacokinetics of imipenem in different populations for individualized dosing: a systematic review

Frontiers in Pharmacology
BackgroundImipenem is a broad-spectrum carbapenem antibiotic for severe infections with significant pharmacokinetic (PK) variability. This review systematically synthesized published population pharmacokinetic (popPK) studies to identify key covariates ...
Ping Zhang, Yuhua Zhao, Jianping Zhu, Yi Yang, Gang Liang, Xia Wang, Zhenwei Yu, Zhenwei Yu   +7 more
doaj   +1 more source

Evaluation the antibacterial activity of nanoantibiotics imipenem and ciprofloxacin loaded in human serum albumin against some antibiotic-resistant pathogenic bacteria

Journal of Experimental Nanoscience, 2020
Introduction Microbial resistance is increasing worldwide. Investigations are underway to use nanoparticles as antimicrobial agents to reduce microbial resistance.
Shima Shafiei, Mehdi Hassanshahian, Shahryar Shakeri, Homa Hamayeli   +3 more
doaj   +1 more source